Search

Your search keyword '"Barker, Juliet N."' showing total 1,028 results

Search Constraints

Start Over You searched for: Author "Barker, Juliet N." Remove constraint Author: "Barker, Juliet N."
1,028 results on '"Barker, Juliet N."'

Search Results

202. The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission

203. Double Unit Cord Blood Transplantation (dCBT) Progression-Free Survival (PFS) is Unaffected by Grade III-IV Acute Graft-Versus-Host Disease (aGVHD) and Survivors Are Likely to Discontinue Immunosuppression (IS) and Reconstitute T-Cells

204. Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative Adult Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

206. Members of the Intestinal Microbiota Are Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

207. Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis

208. Prospective Evaluation of Cord Blood (CB) and Haplo-Identical (Haplo) Donor Availability Reveals Compromised Donor Access for Both CB and Haplo Grafts in Minority Patients

209. CD34+ Selected Ex-Vivo T-Cell Depleted (TCD) Grafts for Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) and High Chronic-Gvhd/Relapse-Free Survival

210. High Progression-Free Survival (PFS) in Adult Double Unit Cord Blood (dCB) Transplant Recipients with High Risk Disease after a Novel Intermediate Intensity Conditioning Regimen

211. Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies

212. The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

213. Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines

214. Prospective Evaluation of Cord Blood (CB) & Haplo-Identical Donor Availability Reveals Compromised Donor Access for Both Graft Types in Minorities and High Rates of Failure to Clear Haplo Donors in Adult Patients

215. Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience

216. A Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Hodgkin Lymphoma

217. Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

220. 549 - Analysis of Cytomegalovirus (CMV) Infections in the First 180 Days in Adult Sero-Positive Cord Blood Transplantation (CBT) Recipients Reveals High Infection Rates and Treatment Burden

222. 465 - Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia

224. 198 - Therapeutic Cyclosporine-a (CSA) Levels in the First 7 Days after Cord Blood Transplantation (CBT) Are Critical to Prevent Severe Acute Graft-Versus-Host Disease (aGVHD)

225. 197 - Long-Term Follow-Up of Adult Double Unit Cord Blood (CB) Transplantation (dCBT) Recipients Reveals High Rates of Progression-Free Survival after a Novel Cy/ Flu/ Thio/ TBI 400 Intermediate Intensity Conditioning Regimen

226. Paradoxical immune reconstitution inflammatory syndrome associated with disseminated tuberculosis infection in an unrelated donor cord blood transplant recipient.

227. CD34+cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking

229. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in 1st complete remission with a decreased risk of graft-versus-host disease

230. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation

231. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation

233. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission : a comparison with allografts from adult unrelated donors.

234. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy

236. Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect

237. Day 45 Lymphocyte Recovery Is Independently Associated with Transplant-Related Mortality after Adult Myeloablative Double-Unit Cord Blood Transplantation (dCBT)

238. Successful Salvage of High-Risk B-Cell Non-Hodgkin and Hodgkin Lymphoma with Double-Unit Cord Blood Transplantation Provides a Platform for Further Optimization

239. Autoimmune Hemolysis & Immune Thrombocytopenic Purpura after Cord Blood Transplantation (CBT) May be Life-Threatening & Warrants Early Therapy with Rituximab

240. Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical CD34+ Selected Peripheral Blood Stem Cells (PBSC) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection and Frequent Pre-Engraftment Syndrome

241. Myeloablative Double-Unit Cord Blood Transplantation (CBT) in Pediatric Patients with High-Risk Acute Leukemia Demonstrates Encouraging Disease-Free Survival with Both TBI and Chemotherapy-Only-Based Conditioning

242. Third Party Donor Derived CMV Specific T Cells for the Treatment of Refractory CMV Viremia and Disease after Hematopoietic Stem Cell Transplant

243. Allogeneic Transplantation for Chronic Myelomonocytic Leukemia (CMML) Is Associated with High Disease-Free Survival Even in the Setting of High-Risk Disease

245. Disease-Free Survival in Adult Patients with Acute Leukemia and Advanced CML Supports Use of Double-Unit Cord Blood Grafts As an Immediate Alternative to 8/8 HLA-Matched Unrelated Donors (URD)

246. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice

247. 67 - Using Haplogictm & Recipient Ancestry: The Likelihood of Identifying an 8/8 HLA-Matched Unrelated Donor Can be Accurately Predicted at the Time of the Preliminary Search Markedly Improving Search Efficiency & Speed to Allograft: An 830 Patient Analysis

248. 262 - Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark Analysis

Catalog

Books, media, physical & digital resources